Inside Nephrology: A Weekly Review
Nefrologia
Advances in Nephrology: CKD Management and Transplant Outcomes
This week we discuss combination therapies for CKD management, transplant outcomes in glomerulopathies, and novel approaches to assessing microvascular health in post-viral syndromes.
Bibliography
1. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
2. Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation.
Authors: Ruiz-Cabello JE, Yandian F, Torres IB, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42462202
DOI: 10.2215/CJN.0000001117
3. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.
Authors: McGill JB, Green JB, Heerspink HJL, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42297748
DOI: 10.1111/dom.70949
4. Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.
Authors: Dixon BP, Laskin BL, Goodwin Davies AJ, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42329702
DOI: 10.2215/CJN.0000001118
5. Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial.
Authors: Tavenier J, Berglind M, Hach LF, et al.
Journal: Basic & clinical pharmacology & toxicology, 2026 Sep
PMID: 42633989
DOI: 10.1111/bcpt.70290
6. A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes.
Authors: Elmorsy YH, Elshal AM, El-Nahas AR, et al.
Journal: Prostate cancer and prostatic diseases, 2026 Sep
PMID: 41198920
DOI: 10.1038/s41391-025-01040-0
7. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Journal of the American Society of Nephrology : JASN, 2026 Sep 1
PMID: 41905767
DOI: 10.1681/ASN.0000001071
8. Microvascular remodeling and endothelial dysfunction across the post-COVID-19 spectrum: a prospective observational case-control study.
Authors: Wallraven T, Günthner R, Lethen I, et al.
Journal: BMC medicine, 2026 Aug 19
PMID: 42625188
DOI: 10.1186/s12916-026-05144-9
9. Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.
Authors: Ono T, Okada T, Takahashi N, et al.
Journal: Blood advances, 2026 Aug 25
PMID: 42275565
DOI: 10.1182/bloodadvances.2026019701
10. Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.
Authors: Zhao X, Liu B, Sun R, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42332386
DOI: 10.1111/jdi.70368
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
2. Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation.
Authors: Ruiz-Cabello JE, Yandian F, Torres IB, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42462202
DOI: 10.2215/CJN.0000001117
3. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.
Authors: McGill JB, Green JB, Heerspink HJL, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42297748
DOI: 10.1111/dom.70949
4. Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.
Authors: Dixon BP, Laskin BL, Goodwin Davies AJ, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Sep 1
PMID: 42329702
DOI: 10.2215/CJN.0000001118
5. Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial.
Authors: Tavenier J, Berglind M, Hach LF, et al.
Journal: Basic & clinical pharmacology & toxicology, 2026 Sep
PMID: 42633989
DOI: 10.1111/bcpt.70290
6. A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes.
Authors: Elmorsy YH, Elshal AM, El-Nahas AR, et al.
Journal: Prostate cancer and prostatic diseases, 2026 Sep
PMID: 41198920
DOI: 10.1038/s41391-025-01040-0
7. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Journal of the American Society of Nephrology : JASN, 2026 Sep 1
PMID: 41905767
DOI: 10.1681/ASN.0000001071
8. Microvascular remodeling and endothelial dysfunction across the post-COVID-19 spectrum: a prospective observational case-control study.
Authors: Wallraven T, Günthner R, Lethen I, et al.
Journal: BMC medicine, 2026 Aug 19
PMID: 42625188
DOI: 10.1186/s12916-026-05144-9
9. Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.
Authors: Ono T, Okada T, Takahashi N, et al.
Journal: Blood advances, 2026 Aug 25
PMID: 42275565
DOI: 10.1182/bloodadvances.2026019701
10. Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.
Authors: Zhao X, Liu B, Sun R, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42332386
DOI: 10.1111/jdi.70368
